Skip to main content

Table 1 Sociodemographic and clinico-immunological characteristics at ART initiation by cohort, Arua, Uganda, 2006

From: Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda

Patient characteristics M12 cohort M24 cohort
  Eligible
(N = 70)
Surveyed
(N = 59)
Eligible
(N = 32)
Surveyed
(N = 27)
Demographic factors     
   Girls (%) 32 (45) 28 (47.5) 14 (44) 11 (40.7)
   Median age, years [IQR] 5.4 [3.2 -8.2] 5.6 [3.2-8.3] 5.5 [4.2-7.7] 5.1 [4.2-7.5]
   Age group (%)     
12-35 months 13 (18.6) 12 (20.3) 6 (18.8) 5 (18.5)
36-59 months 19 (27.1) 14 (23.7) 6 (18.8) 6 (22.2)
5-14 years 38 (54.3) 33 (55.9) 20 (62.4) 16 (59.3)
Treatment history     
   ARV naïve (%) 67 (95.7) 56 (94.9) 31 (96.9) 26 (96.3)
   Median follow-up without ARVs, months [IQR] 5.9 [3.5-11.1] 6.9 [4.2-13.3] 6.3 [1.7-12.0] 6.4 [1.7-12.3]
Clinical factors     
   Clinical stage (%) n = 68 n = 58 n = 32 n = 27
Stage 1/2 16 (23.6) 13 (25.9) 7 (21.9) 5 (18.5)
Stage 3 44 (63.2) 36 (62.1) 18 (56.2) 15 (55.6)
Stage 4 9 (13.2) 7 (12.0) 7 (21.9) 7 (25.9)
   Weight-for-height z-score n = 62 n = 52 n = 29 n = 25
Median [IQR] -1.1
[-2.0 to -0.5]
-1.2
[-2.1 to -0.6]
-0.8
[-1.6 to -0.1]
-0.8
[-1.8 to -0.3]
< -2 score (%) 17 (27.4) 15 (28.8) 3 (10.3) 3 (12.0)
ART regimen (%)     
   AZT 3TC NVP 54 (77.1) 49 (83.1) 25 (78.1) 21 (77.8)
   d4T 3TC NVP 16 (22.9) 10 (17.0) 7 (21.9) 6 (22.2)
CD4 testing, median [IQR]     
   CD4 cell count a n = 14 n = 11 n = 17 n = 15
  190 [106-302] 200 [166-302] 70 [22-149] 70 [20-152]
   CD4% b n = 12 n = 10 n = 2 n = 2
  10 [8-14] 11 [8-14] 14 [10-17] 13 [10-17]
  1. Note: ART, antiretroviral therapy; 3TC, lamivudine; d4T, stavudine; NVP, nevirapine; AZT, zidovudine.
  2. a Number of children aged ≥ 5 years in M12 = 38 and in M24 = 20.
  3. b Number of children aged < 5 years in M12 = 32 and in M24 = 12.